JOURNAL of
ONCOLOGICAL
SCIENCES

REVIEW ARTICLE

Post-operative radiotherapy in the management of metastatic inflammatory breast cancer
Received Date : 18 Oct 2018
Accepted Date : 18 Jan 2019
Doi: 10.1016/j.jons.2019.01.001 - Article's Language: EN
J Oncol Sci 5 (2019) 19-22
This is an open access article under the CC BY-NC-ND license
ABSTRACT
With this review, we aimed to describe the role of adjuvant radiotherapy in the therapeutic management of metastatic inflammatory breast cancer, a rare and aggressive disease historically characterized by high rates of recurrence and poor prognosis. In the context of a multimodality approach, Post-Mastectomy Radiotherapy (PMRT) affirms its role as an appriopriate treatment strategy to improve loco-regional tumor control in selected patients. Further validation in prospective trials is required to better define a standardized therapeutic management of this disease.
KAYNAKLAR
  1. Rea D, Francis A, Hanby AM, et al. Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Canc. 2015 Apr 28;112(9):1613e1615. https:// doi.org/10.1038/bjc.2015.115. [Crossref]  [PubMed]  [PMC] 
  2. Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer Staging Manual. eighth ed. Springer International Publishing: American Joint Commission on Cancer; 2017.
  3. Li J, Xia Y, Wu Q, et al. Outcome of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: a population-based study from the SEER program. Oncotarget. 2017 Jul 25;8(30):49370e49379. https://doi.org/10.18632/oncotarget.17217. [Crossref] 
  4. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011 Mar;22(3):515e523. https://doi.org/10.1093/ annonc/mdq345. [Crossref]  [PubMed]  [PMC] 
  5. Yamauchi H, Woodward WA, Valero V, et al. Inflammatory Breast Cancer: what we know and what we need to learn. Oncol. 2012;17(7):891e899. https:// doi.org/10.1634/theoncologist.2012-0039. [Crossref]  [PubMed]  [PMC] 
  6. Akay CL, Ueno NT, Chisholm GB, et al. Primary tumor resection as a component of multimodality treatment may improve local control and survival in stage IV inflammatory breast cancer. Cancer. 2014 May 1;120(9):1319e1328. https:// doi.org/10.1002/cncr.28550. [Crossref]  [PubMed]  [PMC] 
  7. Damast S, Ho AY, Montgomery L, et al. Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4): 1105e1112. https://doi.org/10.1016/j.ijrobp.2009.06.042. [Crossref]  [PubMed] 
  8. Menta A, Fouad TM, Lucci A, et al. Inflammatory breast cancer. What to know about this unique, aggressive cancer. Surg Clin. 2018 Aug;98(4):787e800. https://doi.org/10.1016/j.suc.2018.03.009. [Crossref]  [PubMed] 
  9. Arora J, Sauer SJ, Tarpley M, et al. Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies. Oncotarget. 2017 Apr 18;8(16):25848e25863. https://doi.org/10.18632/ oncotarget.15667. [Crossref] 
  10. Ueno NT, Fernandez JRE, Cristofanilli M, et al. International consensus on the clinical management of inflammatory breast cancer from the morgan welch inflammatory breast cancer research program 10th anniversary conference. J Canc. 2018 Apr 6;9(8):1437e1447. https://doi.org/10.7150/jca.23969. [Crossref]  [PubMed]  [PMC] 
  11. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F. Defining the molecular biology of inflammatory breast cancer. Semin Oncol. 2008 Feb;35(1):41e50. https:// doi.org/10.1053/j.seminoncol.2007.11.015. [Crossref]  [PubMed] 
  12. Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res. 2009;11(1):R9. https:// doi.org/10.1186/bcr2225. [Crossref]  [PubMed]  [PMC] 
  13. Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Canc Res. 2004 Sep 15;10(18 Pt 1):6215e6221. https://doi.org/10.1158/1078-0432.CCR-04-0202. [Crossref]  [PubMed] 
  14. Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):474e484. https://doi.org/10.1016/ j.ijrobp.2008.01.039. [Crossref]  [PubMed]  [PMC] 
  15. Le Scodan R, Stevens D, Brain E, et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol. 2009 Mar 20;27(9):1375e1381. https://doi.org/10.1200/JCO.2008.19.5396. [Crossref]  [PubMed] 
  16. Takiar V, Akay CL, Stauder MC, et al. Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. SpringerPlus. 2014 Mar 31;3:166. https://doi.org/10.1186/2193-1801-3-166. [Crossref]  [PubMed]  [PMC] 
  17. Budach W, Matuschek C, Bolke E, et al. DEGRO practical guidelines for radiotherapy of breast cancer V- Therapy for locally advanced and inflammatory breast cancer, as well as local therapy in cases with synchronous distant metastases. Strahlenther Onkol. 2015 Aug;191(8):623e633. https://doi.org/ 10.1007/s00066-015-0843-1. [Crossref]  [PubMed]  [PMC] 
  18. Huang EH, Strom EA, Valero V, et al. Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):490e496. https://doi.org/10.1016/ j.ijrobp.2006.08.040.
  19. Harris EE, Schultz D, Bertsch H, Fox K, Glick J, Solin LJ. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1200e1208. [Crossref] 
  20. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1191e1200. [Crossref] 
  21. Thames Jr HD, Peters LJ, Withers HR, Feltcher GH. Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. Int J Radiat Oncol Biol Phys. 1983 Feb;9(2):127e138. [Crossref] 
  22. Possanzini M, Greco C. Stereotactic radiotherapy in metastatic breast cancer. Breast. 2018 Oct;41:57e66. https://doi.org/10.1016/j.breast.2018.06.011. [Crossref]  [PubMed] 
  23. Lancia A, Ingrosso G, Carosi A, et al. Oligometastatic cancer: stereotactic ablative radiotherapy for patients affected by isolated body metastasis. Acta Oncol. 2017 Nov;56(11):1621e1625. https://doi.org/10.1080/0284186X.2017.1346383. [Crossref]  [PubMed]